Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
| STANDARD BIOTOOLS INC.FLDM · Entity 6116 | Director | April 01, 2022 | April 04, 2022 |
| Twist Bioscience CorpTWST · Entity 3619 | Director | November 21, 2022 | November 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,436 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 5,436 F1: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
STANDARD BIOTOOLS INC.
Report date April 01, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Barthelemy 2001 Trust | 204,077 |
Reported balance
After 2022-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-04-01 · Exercise / conversion · Acquired 20,993 · Balance 204,077 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-01 · Exercise / conversion · Disposed 20,993 · Balance 0 |
Twist Bioscience Corp
Report date November 21, 2022 · Filed November 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,021 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Exercise / conversion · Acquired 9,082 · Balance 23,021 |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 11,279 |
Reported balance
After 2022-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-21 · Exercise / conversion · Disposed 9,082 · Balance 11,279 F1: 1/3 of the shares subject to the option vest and become exercisable on the first anniversary of October 24, 2020, and 1/3rd of the shares subject to the option vest and become exercisable on each anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the shares subject to the option vest and become exercisable on the first anniversary of October 24, 2020, and 1/3rd of the shares subject to the option vest and become exercisable on each anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
908 Devices Inc.
Report date June 15, 2022 · Filed June 17, 2022
Section 16 reporting ended · disclosed 2022-06-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 15,379 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Exercise / conversion · Acquired 1,379 · Balance 15,379 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-15 · Exercise / conversion · Disposed 1,379 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnote | 13,541 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,541 F2: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: These securities are owned directly by The Barthelemy 2001 Trust. The reporting person and his spouse are trustees of The Barthelemy 2001 Trust and have joint voting and dispositive control with respect to all securities held by The Barthelemy 2001 Trust and may be deemed to be the beneficial owner of the securities held by The Barthelemy 2001 Trust.
F3: The RSUs became fully vested on June 15, 2022, the day prior to the 2022 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2018 Filed Feb 15, 2018 22:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 7,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000015 · wf-form4_151873523144818.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 23,862 F1 · shares: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Subject to the Reporting Person's continued service with the Issuer through each applicable vesting date, twenty-five percent (25%) of the shares underlying the Restricted Stock Units shall vest quarterly on the last day of each quarter during 2018. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:52 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 4,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000006 · wf-form4_151501631143033.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 0 Underlying: Common Stock · 4,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:52 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 4,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000006 · wf-form4_151501631143033.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 16,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 4,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000153 · wf-form4_150699211954563.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 4,611 Underlying: Common Stock · 4,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 4,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000153 · wf-form4_150699211954563.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Barthelemy 2001 Trust Disclosed balance after: 11,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:06 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001162194-17-000129 · wf-form4_150543755039519.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: 1/12th of the total number of shares subject to the Option will vest each month after the Vesting Commencement Date, on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that the Option will be fully vested one year following the Vesting Commencement Date, subject to recipient continuing to serve as a director of the Company through each such vesting date. "Vesting Commencement Date" shall mean August 1, 2017. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:06 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000129 · wf-form4_150543755039519.xml · derivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. F2 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 20:44 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 9,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000109 · wf-form4_150239784080227.xml · derivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,223 Underlying: Common Stock · 9,223 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:33 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001162194-17-000083 · wf-form4_150172036755393.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: 1/12th of the shares subject to the Option will vest monthly, subject to continued service as a director, such that the Option will be fully vested on August 1, 2018. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:33 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000083 · wf-form4_150172036755393.xml · derivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. F2 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| May 18, 2017 Filed May 22, 2017 20:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,434 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001140361-17-021756 · doc1.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,434 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 20:56 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021756 · doc1.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988 F1 · shares: Mr. Barthelemy was awarded 1,206 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 18, 2018. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001162194-17-000035 · wf-form4_149063590673730.xml · derivative · entry 3 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-03-23 F4 · derivative.exercise_date: 25% of the shares subject to the Option will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000035 · wf-form4_149063590673730.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F3 · derivative.exercise_date: 25% of the shares underlying the Restricted Stock Units will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F3 · derivative.expiration_date: 25% of the shares underlying the Restricted Stock Units will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.